



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/00, 47/18	A1	(11) International Publication Number: WO 99/36055 (43) International Publication Date: 22 July 1999 (22.07.99)
(21) International Application Number: PCT/EP99/00160 (22) International Filing Date: 13 January 1999 (13.01.99) (30) Priority Data: 98810016.0 15 January 1998 (15.01.98) EP (71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT). (72) Inventor; and (75) Inventor/Applicant (for US only): KIS, György, Lajos [CH/CH]; Keberlistrasse 21, CH-8273 Triboltingen (CH). (74) Agent: BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: AUTOCLAVABLE PHARMACEUTICAL COMPOSITIONS CONTAINING A CHELATING AGENT (57) Abstract <p>The present invention describes an autoclavable ophthalmic composition comprising an ophthalmically effective drug. The invention further relates to a method for stabilizing an ophthalmic drug.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AUTOCLAVABLE PHARMACEUTICAL COMPOSITIONS CONTAINING A CHELATING AGENT

The present invention describes an autoclavable ophthalmic composition comprising an ophthalmic drug and in particular an ophthalmic drug. The invention further describes a method for stabilizing such compositions and the use of said stabilizers.

Drug safety is a permanent issue in drug regulatory affairs. A recent European regulation requires that a final ophthalmic composition must be autoclaved before use, and consequently, before sale. Autoclaving improves drug safety since the pathogenic germs are killed thereby.

JP 62/277323 describes for example a method for producing eye drops containing ketotifen fumarate, which eye drops might further contain a preservative such as benzalkonium chloride. In order to stabilize such a composition, JP 62/277323 proposes to add a polyvalent alcohol such as a saccharide and other alcohols such as glycerol or propylene glycol. The composition described is not stable if autoclaved.

Therefore the problem to be solved consists of providing in particular an aqueous ophthalmic composition comprising an ophthalmic drug, in particular selected from ketotifen and dexamethasone, which substantially prohibits decomposition when subjected to standard autoclaving conditions.

This problem had unexpectedly been solved by the addition of a stabilizer which is selected from the group consisting of EDTA, Dequest and Desferal. Preference is given to EDTA and Dequest and more particular to EDTA.

Another unexpected finding of the present invention is a synergistic effect, namely the effect of improved preservative efficacy if a preservative is added to said stabilized composition. This means that the amount preservative necessary to ensure shelf life and multi-dose sterility may be reduced very significantly, which in turn may strongly improve ocular tolerability of an addressed ophthalmic composition.

Consequently, the invention relates to an ophthalmic composition in accordance to the main claim. It further relates to the objects of all dependent and independent claims disclosed

infra, in particular to a method of stabilizing an ophthalmic drug by adding a particular stabilizer during autoclavation.

According to the invention an ophthalmic composition is advantageously applied topically to the eye, especially in the form of a solution, a suspension or a gel. Such compositions comprise an ophthalmically effective ingredient and in particular ketotifen or dexamethasone, for example, in a range of from approximately 0.000001 to approximately 10.0% by weight, preferably from approximately 0.00001 to approximately 1.0% by weight, or more preferably in the range of from approximately 0.0001 to approximately 0.1% by weight and most preferably in the range of from 0.001 to 0.1% by weight. The dose of the active ingredient may depend on various factors, such as mode of administration, requirement, age and/or individual condition.

Other customary pharmaceutically acceptable excipients and additives known to the person skilled in the art are used in corresponding ophthalmic composition. Such compositions are prepared in a manner known per se, for example by mixing an active ingredient with the corresponding excipients and/or additives to form corresponding ophthalmic compositions.

Carriers used in accordance to the present invention are typically suitable for topical or general administration, and are for example water, mixtures of water and water-miscible solvents, such as C₁- to C₇-alkanols, vegetable oils or mineral oils comprising from 0.5 to 5% by weight hydroxyethylcellulose, ethyl oleate, carboxymethyl-cellulose, polyvinylpyrrolidone and other non-toxic water-soluble polymers for ophthalmic uses, such as, for example, cellulose derivatives, such as methylcellulose, alkali metal salts of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose, hydroxypropylcellulose, chitosan and scleroglucan, acrylates or methacrylates, such as salts of polyacrylic acid or ethyl acrylate, polyacrylamides, natural products, such as gelatin, alginates, pectins, tragacanth, karaya gum, xanthan gum, carrageenin, agar and acacia, starch derivatives, such as starch acetate and hydroxypropyl starch, and also other synthetic products, such as poloxamers, e.g. Poloxamer F127, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, polyethylene oxide, preferably cross-linked polyacrylic acid, such as neutral Carbopol, or mixtures of those polymers. Preferred carriers are water, cellulose derivatives, such as methylcellulose, alkali metal salts of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropyl-

cellulose and hydroxypropylcellulose, neutral Carbopol, or mixtures thereof. The concentration of the carrier is, for example, from 0.1 to 100000 times the concentration of the active ingredient.

Solubilizers may be used for an ophthalmic composition of the present invention as well, and are, for example, tyloxapol, fatty acid glycerol polyethylene glycol esters, fatty acid polyethylene glycol esters, polyethylene glycols, glycerol ethers, polysorbate 20, polysorbate 80 or mixtures of those compounds. A specific example of an especially preferred solubilizer is a reaction product of castor oil and ethylene oxide, for example the commercial products Cremophor EL® or Cremophor RH 40®. Reaction products of castor oil and ethylene oxide have proved to be particularly good solubilizers that are tolerated extremely well by the eye. Another preferred solubilizer is tyloxapol. The concentration used depends especially on the concentration of the active ingredient. The amount added is typically sufficient to solubilize the active ingredient. For example, the concentration of the solubilizer is from 0.1 to 5000 times the concentration of the active ingredient.

Buffers, tonicity enhancing agents and preservatives different from quaternary ammonium salts may be used in an ophthalmic composition of the present invention too.

Examples of buffer substances are acetate, ascorbate, borate, hydrogen carbonate /carbonate, citrate, gluconate, lactate, phosphate, propionate and TRIS (tromethamine) buffers. Tromethamine and borate buffer are preferred buffers. The amount of buffer substance added is, for example, that necessary to ensure and maintain a physiologically tolerable pH range. The pH range is typically in the range of from 4 to 9, preferably from 4.5 to 8.5 and more preferably from 5.0 to 8.2.

Tonicity enhancing agents may also be present in an above composition and are, for example of ionic and/or non-ionic type. Examples of ionic tonicity enhancers are e.g. alkali metal or earth metal halides, such as, for example, CaCl_2 , KBr, KCl, LiCl, NaI, NaBr or NaCl, Na_2SO_4 or boric acid. Non-ionic tonicity enhancing agents are, for example, urea, glycerol, sorbitol, mannitol, propylene glycol, or dextrose. Typically, a sufficient amount of tonicity enhancing agent may be added to impart to an above ophthalmic composition an osmolality of approximately from 50 to 1000 mOsmol, preferred from 100 to 400 mOsmol, more preferred from 200 to 400 mOsmol and even more preferred from 250 to 350 mOsmol.

Preservatives may be present in an above composition too. A preservative may typically be selected from a quaternary ammonium compound such as benzalkonium chloride, benzoxonium chloride or the like. Benzalkonium chloride is better described as: N-benzyl-N-(C₈-C₁₈alkyl)-N,N-dimethylammonium chloride. Examples of preservatives different from quaternary ammonium salts are alkyl-mercury salts of thiosalicylic acid, such as, for example, thiomersal, phenylmercuric nitrate, phenylmercuric acetate or phenylmercuric borate, parabens, such as, for example, methylparaben or propylparaben, alcohols, such as, for example, chlorobutanol, benzyl alcohol or phenyl ethanol, guanidine derivatives, such as, for example, chlorohexidine or polyhexamethylene biguanide, sodium perborate, Germal®II or sorbic acid. Preferred preservatives are quaternary ammonium compounds, in particular benzalkonium chloride, alkyl-mercury salts and parabens. Where appropriate, a sufficient amount of preservative is added to the ophthalmic composition to ensure protection against secondary contaminations during use caused by bacteria and fungi.

Another object of the present invention are autoclavable ophthalmic compositions in accordance to the specification and the claims, but with the proviso that the preservative is absent. Such compositions are in particular useful for the so called unidose forms.

An above ophthalmic composition may comprise further non-toxic excipients, such as, for example, emulsifiers, wetting agents or fillers, such as, for example, the polyethylene glycols designated 200, 300, 400 and 600, or Carbowax designated 1000, 1500, 4000, 6000 and 10000. Other excipients that may be used if desired are listed below but they are not intended to limit in any way the scope of the possible excipients. Such excipients are especially antioxidants, such as ascorbic acid, acetylcysteine, cysteine, sodium hydrogen sulfite, butyl-hydroxyanisole, butyl-hydroxytoluene or alpha-tocopherol acetate. The amount and type of excipient added is in accordance with the particular requirements and is generally in the range of from approximately 0.0001 to approximately 90% by weight.

Further excipients may be comprised in an above concerned ophthalmic composition, which may in particular function as a combined stabilizer/solubilizer. Such a combined additional stabilizer/solubilizer is for example a cyclodextrin. A preferred cyclodextrin is in particular selected from the group of α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, hydroxypropyl- β -cyclodextrin, hydroxypropyl- γ -cyclodextrin, dimethyl- β -cyclodextrin and dimethyl- γ -

cyclodextrin. The amount is generally in the range of from approximately 0.01 to approximately 90% by weight, more preferably in the range of from 0.1 - 20% by weight.

Alkyl means throughout this invention an alkyl group having up to and including 18, more preferably 12 and even more preferably 7 C-atoms, and is either a linear or a branched alkyl group.

Examples for alkyl are methyl, ethyl, propyl, butyl, iso-propyl, t-butyl, neo-pentyl, octyl or dodecyl.

The term weight % used herein refers to the weight % of the total weight of an addressed composition or object.

The above is in particular useful for ophthalmic drugs. Examples of such ophthalmic drugs are antazolin, betaxolol, bupivacaine, carbachol, carteolol, chloramphenicol, chlortetracycline, cromolyn sodium, dexamethasone, dichlorphenamide, dipivefrin, ephedrine, erythromycin, fluoromethalone, indomethacin, ketotifen, levobunolol, levocabastine, lidocaine, lignocaine, lomefloxacin, medrysone, methazolamide, naphazoline, natamycin, neomycin, noradrenaline, ofloxacin, oxybuprocaine, physostigmine, pilocarpine, polymyxin B, prednisolone, scopolamine, sorbinil, sulfacetamide, tamoxifen, tetracaine, tetracycline, timolol, trifluridine, tropicamide, vidarabine, and ophthalmically acceptable salts, and mixtures thereof.

More preferred ophthalmic drug are selected from antazolin, betaxolol, chloramphenicol, dexamethasone, fluoromethalone, ketotifen, lomefloxacin, ofloxacin, pilocarpine, timolol and ophthalmically acceptable salts, and mixtures thereof.

Strongly preferred are ketotifen and dexamethasone.

The term ketotifen relates to the basic compound itself as well to any pharmaceutically acceptable salt thereof. A preferred pharmaceutically acceptable salt of ketotifen is for example a hydrochloride, a hydrobromide, a hydrogen maleate, a hydrogen sulfate and a hydrogen fumarate. A more preferred example is a hydrochloride and a hydrogen fumarate. Most preferred is a hydrogen fumarate.

Similarly, the term dexamethasone relates also e.g. to dexamethasone-21-acetate, dexamethasone-21-phosphate disodium salt, dexamethasone-21-dihydrogen phosphate disodium salt and the like. All these are known to the skilled person in the art and are specifically disclosed in Merck Index, 12 th edition, page 498, No. 2986.

The term autoclaving relates to a standardized thermal heating procedure characterized by the following parameters:

Heating a test composition to 120°C or more for a period of 15 minutes or more, wherein said composition is aqueous. Said aqueous composition is kept in a closed vessel, which vessel is typically a plastic or glass bottle. A preferred bottle material is polypropylene (PP). The pressure during autoclaving is typically 1 bar or more.

The autoclaving (autoclavation) may preferably range from 120 - 150°C, more preferably from 120 - 140°C; the time needed may preferably range from 15 - 120 minutes, more preferably from 15 - 60 minutes; and the pressure applied may preferably range from 1 - 20 bar, more preferably from 1 - 10 bar, and even more preferably from 1 - 5 bar.

The term Dequest as used within the present invention relates to chelating agents having phosphonic acid or phosphonate groups. A preferred group of such chelating agents are organophosphonates, particularly amino tri(lower alkylene phosphonic acids). A variety of such chelating agents are commercially available from Monsanto Company, St. Louis, Missouri, and are sold under the trademark DEQUEST®. Examples of such compounds include, without limitation, diethylene triamine penta(methylene phosphonic acid); hexamethylene-diaminetetra (methylenephosphonic acid); ethylenediaminetetra (methylene-phosphonic acid); and aminotrimethylene phosphonates. A particularly preferred chelating agent is diethylene triamine penta(methylene phosphonic acid), sold under the trademark DEQUEST® 2060. Mixtures of such Dequests mentioned above may be comprised too.

Within the terms of the present invention, EDTA relates to ethylenediamine tetraacetic acid itself as well to its various salts, namely e.g. to monosodium, disodium and/or potassium salts. EDTA may also be referred to as edetate. Mixtures of EDTA's may be comprised too.

Desferal relates within the present terms to deferoxamine itself (see Merck Index 12 th edition, page 483, No. 2914) as well to its salts, e.g. hydrochloride, methanesulfonate and

the like. Derivatives thereof, such as N-acetyldeferoxamine may also be comprised. Mixtures of such deferoxamines may be comprised too.

Typical examples which illustrate the present invention, but are not intended to limit it in any way, are described below.

Example 1, eye drop formulations

ketotifen hydrogen fumarate	0.069 mg	0.069 mg	0.069 mg	0.069 mg
random methyl- β -cyclodextrin,	2.000 g	10.000 g		
hydroxypropyl- γ -cyclodextrin			2.000 g	10.000 g
propylene glycol	1.900 g	1.900 g	1.900 g	1.900 g
disodium edetate	0.050 g	0.050 g	0.050 g	0.050 g
benzalkonium chloride	0.010 g	0.010 g	0.010 g	0.010 g
sodium hydroxide 1 N	q.s.	q.s.	q.s.	q.s.
water for injections ad	100 ml	100 ml	100 ml	100 ml
pH	5.91	5.85	5.76	5.80
Osmolality (mOsmol)	287	292	292	295

Example 2, eye drop formulations

ketotifen hydrogen fumarate	0.069 mg	0.069 mg	0.069 mg	0.069 mg
random methyl- β -cyclodextrin,	2.000 g	10.000 g		
hydroxypropyl- γ -cyclodextrin			2.000 g	10.000 g
propylene glycol	1.900 g	1.900 g	1.900 g	1.900 g
disodium edetate	0.050 g	0.050 g		
benzalkonium chloride	0.010 g	0.010 g	0.010 g	0.010 g
sodium hydroxide 1 N	q.s.	q.s.	q.s.	q.s.
water for injections ad	100 ml	100 ml	100 ml	100 ml
pH	7.19	7.25	7.16	7.22
Osmolality (mOsmol)	277	285	283	290

Example 3, Ketotifen 0.025% Eye Drops

Samples in 10 ml white-colored PP-bottles

Composition (%)	A	B	Comparative
ketotifen hydrogen fumarate	0.0345	0.0345	0.0345
glycerol, pure compound	2.550	2.125	2.125
disodium edetate	0.05	0.05	--
benzalkonium chloride	0.01	0.01	0.01
sodium hydroxide 1N	0.083	0.080	0.074
water for injection ad	100 ml	100 ml	100 ml

0-Value

content of ketotifen hydrogen fumarate in %	100.1	100.5	101.5
pH	5.31	5.29	5.32
Osmolality (mOsmol)	300	244	240

Stresstest 15 hrs 80°C

content of ketotifen hydrogen fumarate in %	100.4	98.7	99.4
degradation products in %	n.d.	n.d.	0.03
pH	5.28	5.24	5.27
Osmolality (mOsmol)	300	251	238

Autoclaved, 120°C, 20 min., 1.5 bar pressure

content of ketotifen hydrogen fumarate in %	98.2		96.5
degradation products in %	n.d.		0.23
pH	5.31		5.18
Osmolality (mOsmol)	299		238

n.d. = not detectable

Example 4, Spersadex 0.1% eye drops

Sample	A	B	C
(Ingredients in g unless indicated differently)			
dexamethasone sodium phosphate	0.100	0.100	0.100
boric acid	1.800	1.800	1.800
sodium borate	0.250	0.250	0.250
BAK (benzalkonium chloride)	0.010	0.010	0.010
Cremophor EL	1.000	1.000	1.000
HPMC (hydroxypropyl methylcellulose)	0.200	0.200	0.200
disodium edetate	-	0.050	-
Dequest 2060	-	-	0.013
water for injection ad	100 ml	100 ml	100 ml

O-Value

% dexamethasone sodium phosphate	101.4	101.7	101.5
pH	7.14	7.10	7.11
Osmolality (mOsmol)	313	323	316

Autoclaved (10 ml PP-bottles, 120°C, 20 minutes, 1.5 bar)

% dexamethasone sodium phosphate	89.3	93.6	92.2
pH	7.15	7.13	7.14
Osmolality (mOsmol)	314	319	320

Autoclaved (10 ml glass-bottles, 120°C, 20 minutes, 1.5 bar)

% dexamethasone sodium phosphate	88.4	93.3	92.0
pH	7.15	7.15	7.12
Osmolality (mOsmol)	317	321	317

Example 5:

Ketotifen 0.025% Eye Drops. Samples in 5 ml white-colored PP-bottles

Composition (%)	
ketotifen hydrogen fumarate	0.0345
glycerol, pure compound	2.125
disodium edetate	0.05
benzalkonium chloride	0.01
sodium hydroxide 1N	0.080
water for injection ad	100 ml

Stresstest

	0-Value	(1): 120°C, 15 bar, 20 min. and (2): 30°C, 3 month
ketotifen hydrogen fumarate	99.5 %	98.3%
degradation products	n.d.	n.d.
pH	5.25	5.27
Osmolality	238 mOsmol	239 mOsmol

The values before [0-value] and after the stresstest [(1): 120°C, 15 bar, 20 min. and (2): 30°C, 3 month] are within the standard deviation of the analytical method. This demonstrates the stability of the above ketotifen eye drops.

Claims

1. An aqueous autoclavable ophthalmic composition comprising an ophthalmic drug and a stabilizer, which stabilizer is a chelating agent.
2. Composition of claim 1, wherein the stabilizer is selected from the group consisting of EDTA, Desferal and Dequest, preferably from EDTA and Dequest, and more preferably from EDTA.
3. A composition according to claim 1, further comprising a preservative, which is preferably selected from the group consisting of sepazonium chloride, cetyltrimethylammonium bromide (cetrimide), cetylpyridinium chloride, benzoxonium chloride, benzethonium chloride, domiphen bromide (Bradosol®) and benzalkonium chloride, and more preferably from benzalkonium chloride and benzoxonium chloride.
4. A composition according to claim 1, further comprising one or more of an excipient selected from the group consisting of buffers, carriers, solubilizers, preservatives, tonicity enhancing agents and fillers.
5. Composition of claim 1, wherein the drug is selected from the group consisting of antazolin, betaxolol, chloramphenicol, dexamethasone, fluoromethalone, ketotifen, lomefloxacin, ofloxacin, pilocarpine, timolol and ophthalmically acceptable salts, and mixtures thereof, preferably from ketotifen and dexamethasone and more preferably from ketotifen.
6. A composition of claim 1 further comprising a cyclodextrin selected from the group of α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, hydroxypropyl- β -cyclodextrin, hydroxypropyl- γ -cyclodextrin, dimethyl- β -cyclodextrin and dimethyl- γ -cyclodextrin.
7. Composition of claim 4, wherein the carrier is selected from water, cellulose derivatives, such as methylcellulose, alkali metal salts of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose and hydroxypropylcellulose, neutral Carbopol and mixtures thereof.

8. Composition of claim 1, wherein the term autoclavable relates to a thermal treatment of an aqueous composition in a closed vessel at 120°C or more, for 15 minutes or more, and at 1 bar pressure or more.

9. Composition of claim 8, wherein the vessel is a glass or PP-bottle and preferably a PP-bottle.

10. Method of stabilizing an ophthalmic composition comprising an ophthalmic drug, comprising the steps of:

- (a) providing an ophthalmically compatible carrier further comprising an ophthalmic drug,
- (b) adding a stabilizer selected from the group consisting of EDTA, Desferal and Dequest,
- (c) transferring these components into a suitable vessel,
- (d) tightly closing said vessel, and
- (e) autoclaving the vessel comprising the above composition at 120°C or more, for 15 minutes or more, and at 1 bar pressure or more.

11. Method of claim 10, wherein the drug is selected from ketotifen and dexamethasone and more preferably from ketotifen.

12. Method of claim 10, wherein the drug is selected from ketotifen and wherein the stabilizer is selected from EDTA.

13. Method of claim 10, wherein the carrier is selected from the group consisting of water and mixtures with water, preferably water.

14. Method of claim 10, which provides drug stability to autoclavation.

15. Use of a stabilizer of claim 2, in the method of claim 10, to prevent the ophthalmic drug of claim 5 from decomposition.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/00160

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/00 A61K47/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 00669 A (CIBA GEIGY) 9 January 1997 see claims 1-6,9-11 see page 3, paragraph 3 ---	1-4
X	EP 0 258 865 A (VISION PHARMACEUTICALS) 9 March 1988 see claims 1,3,10 see examples 1-4 ---	1-4
X	EP 0 719 545 A (MDV TECHNOLOGIES) 3 July 1996 see claims 1,14 see page 7, line 47 - page 8, line 29 see page 11; example 1 ---	1-4
X	US 5 165 918 A (BARBARA L. HEYL, ET AL.) 24 November 1992 see column 2, line 10 - column 3, line 20 ---	1-4
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 June 1999

Date of mailing of the international search report

30/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/00160

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 399 834 A (FISONS) 2 July 1975 see claims 1-6, 14-18, 27 see page 2, line 85 - line 103 ----	1-4
X	GB 2 001 529 A (AMERICAN HOME PRODUCTS) 7 February 1979 see claim 1 see page 1, line 31 - line 45 -----	1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. onal Application No

PCT/EP 99/00160

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9700669 A	09-01-1997	US 5683993 A	04-11-1997
		AU 6355196 A	22-01-1997
		CA 2222646 A	09-01-1997
		EP 0833609 A	08-04-1998
		US 5858996 A	12-01-1999
EP 258865 A	09-03-1988	US 5032392 A	16-07-1991
		AT 58475 T	15-12-1990
		AU 599695 B	26-07-1990
		AU 7797887 A	10-03-1988
		GR 3001098 T	17-04-1992
		GR 3014937 T	31-05-1995
		IN 165608 A	25-11-1989
		JP 2053627 C	23-05-1996
		JP 7051500 B	05-06-1995
		JP 63208516 A	30-08-1988
EP 719545 A	03-07-1996	US 5077033 A	31-12-1991
		US 5071644 A	10-12-1991
		US 5124151 A	23-06-1992
		US 5143731 A	01-09-1992
		US 5376693 A	27-12-1994
		US 5277911 A	11-01-1994
		CA 2044878 A	08-02-1992
		DE 69122008 D	17-10-1996
		DE 69122008 T	30-01-1997
		DK 470703 T	30-09-1996
		EP 0470703 A	12-02-1992
		JP 4230636 A	19-08-1994
		US 5346703 A	13-09-1994
		US 5847023 A	08-12-1998
US 5165918 A	24-11-1992	AU 627195 B	20-08-1992
		AU 3678089 A	04-01-1990
		CA 1332556 A	18-10-1994
		DK 318889 A	29-12-1989
		EP 0349487 A	03-01-1990
		IL 90680 A	12-04-1994
		JP 2048523 A	19-02-1990
		JP 2788493 B	20-08-1998
		PT 90942 A,B	29-12-1989
GB 1399834 A	02-07-1975	AU 465305 B	25-09-1975
		AU 4208072 A	15-11-1973
		BE 782981 A	03-11-1972
		CA 1000201 A	23-11-1976
		CY 955 A	22-12-1978
		DE 2223237 A	14-12-1972
		DE 2266025 A	07-03-1985
		DK 131324 B	30-06-1975
		FR 2139872 A	12-01-1973
		HK 69276 A	12-11-1976
		IE 36337 B	13-10-1976
		JP 54025082 B	25-08-1979
		NL 7206251 A,B	14-11-1972
		SE 396011 B	05-09-1977
		US 3975536 A	17-08-1976
		US 4053628 A	11-10-1977

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/00160

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1399834 A		ZA 7202823 A	28-03-1973
GB 2001529 A	07-02-1979	AT 361124 B	25-02-1981
		AT 551678 A	15-07-1980
		AU 3846578 A	07-02-1980
		BE 869384 A	29-01-1979
		FR 2399249 A	02-03-1979
		JP 54028810 A	03-03-1979
		ZA 7804247 A	27-02-1980